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Background and purpose   Reverse hybrid hip replacement uses a 
cemented all-polyethylene cup and an uncemented stem. Despite 
increasing use of this method in Scandinavia, there has been very 
little documentation of results. We have therefore analyzed the 
results from the Norwegian Arthroplasty Register (NAR), with 
up to 10 years of follow-up.
Patients and methods   The NAR has been collecting data on total 
hip replacement (THR) since 1987. Reverse hybrid hip replace-
ments were used mainly from 2000. We extracted data on reverse 
hybrid THR from this year onward until December 31, 2009, and 
compared the results with those from cemented implants over the 
same period. Specific cup/stem combinations involving 100 cases 
or more were selected. In addition, only combinations that were 
taken into use in 2005 or earlier were included. 3,963 operations in 
3,630 patients were included. We used the Kaplan-Meier method 
and Cox regression analysis for estimation of prosthesis survival 
and relative risk of revision. The main endpoint was revision for 
any cause, but we also performed specific analyses on different 
reasons for revision. 
Results   We found equal survival to that from cemented THR 
at 5 years (cemented: 97.0% (95% CI: 96.8–97.2); reverse hybrid: 
96.7% (96.0–97.4)) and at 7 years (cemented: 96.0% (95.7–96.2); 
reverse hybrid: 95.6% (94.4–96.7)). Adjusted relative risk of revi-
sion of the reverse hybrids was 1.1 (0.9–1.4). In patients under 60 
years of age, we found similar survival of the 2 groups at 5 and 7 
years, with an adjusted relative risk of revision of reverse hybrids 
of 0.9 (0.6–1.3) compared to cemented implants.
Interpretation   With a follow-up of up to 10 years, reverse 
hybrid THRs performed well, and similarly to all-cemented 
THRs from the same time period. The reverse hybrid method 
might therefore be an alternative to all-cemented THR. Longer 
follow-up time is needed to evaluate whether reverse hybrid hip 
replacement has any advantages over all-cemented THR.

The reverse hybrid method (also known as “inverse hybrid”) 
uses a cemented all-polyethylene cup in combination with an 
uncemented stem. This method is partly based on good clini-
cal results of cemented cups and of some uncemented stems 
in the Norwegian Arthroplasty Register (NAR) (Havelin et al. 
2000a,b, Hallan et al. 2007). The register has also shown that 
some uncemented femoral stems may have better long–term 
results (> 10 years) than cemented stems in patients 60 years 
of age or younger. Based on these findings, the NAR suggested 
10 years ago that the use of cemented cups in combination 
with uncemented stems might be justified in young patients 
(Havelin et al. 2000a). In the Swedish Hip Arthroplasty Reg-
ister, the performance of uncemented THR was found to be 
inferior to that of cemented THR (Hailer et al. 2010). The 
authors of that study found that cemented cups performed 
better than uncemented cups and that uncemented femoral 
stems had better survival than cemented stems, with aseptic 
loosening as endpoint. In the Finnish Arthroplasty Registry, 
Mäkelä et al. (2010) found better long-term survival regarding 
aseptic loosening for the best performing types of cementless 
stems compared to the cemented reference group, in the age 
group 55–74 years.
McNally et al. (2000) studied survival of the Furlong HA 
coated femoral stem in combination with a cemented ultra-
high-density polyethylene cup at 10–11 years, and found 
values of 99% for the stem and 95% for the cup. Alho et al. 
(2000) reported results with cemented Lubinus cups and unce-
mented Furlong stems, and they also pointed out the possibil-
ity of using the principle of reverse hybrid arthroplasty. We are 
not aware of any other reports on the reverse hybrid method. 
In a reverse hybrid THR, an uncemented stem and a mod-
ular head are most often combined with a cemented cup of 
another name or from another company. Combining implants 
that are not designed to fit each other might theoretically lead 640  Acta Orthopaedica 2011; 82 (6): 639–645
to unexpected complications such as increased wear, loos-
ening, or dislocation. This concern was raised by the NAR 
already in their report from 2005 (Norwegian Arthroplasty 
Register 2005). As the use of reverse hybrids is increasing, we 
decided to evaluate the short- to medium-term results with this 
concept and to compare them with those from all-cemented 
THRs, using data from the NAR.
Patients and methods
The NAR was established in September 1987 (Havelin et 
al. 1993). Data on primary and revision THR surgery are 
collected, and the patients are followed prospectively until 
revision, death, or emigration. The unique identification 
number assigned to each resident of Norway makes it pos-
sible to link the primary operation to revision surgery and to 
the National Population Register, which provides informa-
tion on death or emigration. Completeness of registration is 
high for total hip replacement, for both primary and revision 
surgery (Arthursson et al. 2005, Espehaug et al. 2006, Hul-
leberg et al. 2008).
From September 1, 1987 through December 31, 2009, 
124,759 primary THRs were registered. Of these, 6,630 cases 
involved reverse hybrid THR. 15 different cups and 13 dif-
ferent femoral stems had been used for these reverse hybrids. 
Since reverse hybrid THR has mainly been used during the 
last decade, we included only operations performed after 
December 31, 1999. This gave 6,485 primary operations. We 
included only the combinations of cup and stem for which 
there had been more than 100 procedures since 2005. Thus, 
3,963 operations in 3,630 patients were included (Figure 1) 
for survival estimation at 5 and 7 years, involving 9 implant 
combinations (cup/stem) (Tables 1 and 2). In these implant 
combinations, all cups were made from conventional ultra-
high-molecular-weight polyethylene (UHMWPE).
From the register, we extracted information on the brand(s) 
of the components, the diameter and the material of the femo-
ral heads, the diagnosis, the name of the hospital, the surgi-
cal approach to the hip, and reasons for revision surgery. We 
estimated survival at 3, 5, and 7 years for the total material 
with any revision as the endpoint. Further subgroup analyses 
included survival at 3, 5, and 7 years in patients less than 60 
years of age, with any revision as endpoint. Furthermore, we 
compared reverse hybrid THR to cemented THR for the total 
material, with deep infection, dislocation, aseptically loos-
Figure 1. Flowchart of the study.
Reverse hybrid THR
n = 6,630
Cemented THR
n = 94,737
2000–2009
>100 in each group and
operated before 2006
n = 3,963
2000–2009
n = 46,326
10 most used 
cemented combinations
n = 37,666
Age <60 years
n = 1,647
Age <60 years
n = 3,480
Elite/ Corail    n = 1,762
Titan/ Corail   n = 722
Kronos/ Corail    n = 527
Reﬂection PE/ Corail  n = 295
Exeter/ABG II    n = 172
Reﬂection PE/Hactiv  n = 126
Exeter/ Corail    n = 142
Charnley/ Corail    n = 105
Reﬂection PE/Taperloc  n = 112
Norwegian Arthroplasty Register 
Sept 1987 – Dec 31, 2009
Primary THRs
n = 124,759 
Table 1. Breakdown of numbers of different combinations of prosthesis components in the reverse hybrid group during the study period 
  Combination of cup and stem (reverse hybrid) 
  Elite/  Titan/  Kronos/  Reflection  Exeter/ Charnley/ Exeter/  Reflection  Reflection  Total
Year  Corail  Corail  Corail PEa/Corail  Corail   Corail  ABG II  PEa/Hactiv PEa/Taperloc
2000  38  3  3  6  1 6 0  0 0 57
2001  43 22  14 13  2 4 0  0 0 98
2002  45 46  6 37  3 7 0  0 0  144
2003  61 50  9  55 8  2  61 0 0  246
2004  83  72  14 63 16  9  50 12  0 319
2005  178  79  39 69 10  5  61 37 34 512
2006  269  82  66 18 11  14  0 29 49 538
2007  365  75  98 26 18  34  0 18 29 663
2008  362 113 157  5 28 13  0 16  0 694
2009  318 180 121  3 45 11  0 14  0 692
Total  1762  722  527  295  142 105 172  126 112 3963
a Full brand name: Reflection Cemented All-Poly.Acta Orthopaedica 2011; 82 (6): 639–645  641
ened stem, and aseptically loosened cup as endpoint in the 
same period.
We compared the results to the 10 most commonly used 
cemented cup/stem combinations in the study period. These 
cemented implants and the cups in the reverse hybrid group 
have been described by Espehaug et al. (2009) (Table 3). 
Details of the stems in the present study are given in Table 4. 
We excluded patients operated with CMW cement, due to the 
poor results described by others after use of this cement (Hav-
elin et al.1995, Espehaug et al. 2002). 
Statistics 
Risk Ratio (RR) with 95% confidence interval (CI) was esti-
mated using Cox regression analyses, with adjustments for 
age (< 50, 50–59, 60–69, 70–79 and > 80), sex, and diagnosis 
(osteoarthritis (OA), inflammatory arthritis, and others). We 
used plots with scaled Schoenfeld residuals for each covariate 
to test that the Cox proportional hazard model was fulfilled. 
The Kaplan-Meier method was used for estimation of survival 
probabilities for the prostheses, with 95% confidence interval 
(CI). Ranstam and Robertsson (2010) have discussed statis-
tical analysis regarding arthroplasty register data and found 
a negligible effect on survival estimates including bilateral 
hips. We therefore included bilateral hips. When less than 
20 hips remained at risk, survival probabilities were not cal-
culated. Median follow-up was calculated using the reverse 
Kaplan-Meier method. We used chi-squared test to test for 
binary outcomes between study groups, and the non-para-
metric Mann-Whitney test was used to determine whether the 
distribution of medians was different between study groups. 
All p-values less than 0.05 were considered to be statisti-
cally significant. We used the statistical software packages 
SPSS (SPSS 17.0 for Windows) and R (version 2.8.1; http://
www.R-project.org).
Table 2. Comparison of different combinations of prosthesis components in the reverse hybrid group 
Brand name  Manufacturer  N  Revisions  Median follow-up  Mean age  % < 60  % male  No. of hospitals
cup/stem  cup/stem      (range)  (min–max)  year    (max % at hospital)
Elite/Corail   Landos Depuy/Depuy  1762  40  2.6 (0–10)  60 (21–92)  48  40  15 (34%)
Titan/Corail  Landos Depuy/Depuy  722  21  3.0 (0–9.8)  63 (27–91)  36  36  11 (34%)
Kronos/Corail  Landos Depuy/Depuy  527  12  1.8 (0–9.7)  63 (20–92)  33  32    4 (83%)
RPE a/Corail   Smith & Nephew/Depuy  295  17  5.6 (0–9.9)  58 (18–90)  58  37  11 (35%)
Exeter/ ABG II  Stryker b/Stryker  172  6  5.4 (1.4–7.0)  73 (50–88)    2  37    2 (82%)
RPE a/Hactiv   Smith & Nephew/Scanos c  126  5  3.6 (0–5.6)  64 (19–91)  38  37    2 (97%)
Exeter/Corail   Stryker b/Depuy  142  2  1.9 (0–9.9)  64 (19–87)  35  18    5 (67%)
Charnley/Corail   Depuy/Depuy  105  2  2.8 (0.4–9.9)  58 (21–86)  61  21  14 (46%)
RPE a/Taperloc   Smith & Nephew/Biomet  112  3  3.8 (2.5–4.7)  61 (40–82)  36  33    1 (100%) 
 
a Full brand name: Reflection Cemented All-Poly.
b Full brand name: Stryker, Osteonics, Howmedica
c Full brand name: Scanos Evolutis
Table 3. Cup/stem combinations in the cemented group. These have been 
thoroughly described by Espehaug et al. (2009)
  Manufacturer  Number of 
   prostheses
Charnley/Charnley Depuy  12,192
Exeter/Exeter  Stryker, Osteonics, Howmedica  6,419
Reflection PE/Spectron  Smith & Nephew  8,618
Titan/Titan  Landos, Depuy  2,736
Spectron/ITH  Smith & Nephew  162
Link IP/Lubinus SP(I,II)  Waldemar Link  2,203
Contemporary/Exeter  Stryker, Osteonics, Howmedica  2,707
Kronos/Titan  Landos, Depuy  1,073
Elite/Titan  Depuy/Landos Depuy  1,139
Reflection/ITH  Smith & Nephew  417
Table 4. Details of the characteristics of the uncemented femoral stems used in the reverse hybrid group. 97% had HA 
coating
Stem   Material  Shape  Surface  Thickness of HA  Company 
Corail  Ti6A14V  Straight, tapered  Fully HA-coated  155 µm  DePuy
ABG II  Ti alloy  Anatomic  HA-coated proximal, polished distally    50 µm  Stryker
Hactiv  Ti6A14V  Straight, tapered  Fully HA-coated  155 µm  Evolutis 
Taperloc  Ti6A14V  Straight, tapered  Without HA in this study, proximal
      plasma spray coating     Biomet642  Acta Orthopaedica 2011; 82 (6): 639–645
Results
The mean age was lower in the reverse hybrid group than in the 
cemented group: 61 (18–92) years as opposed to 73 (16–98) 
years. The proportion of males was higher in the reverse hybrid 
group than in the cemented group (36% vs. 29%). In addition, 
9% of patients were below 60 years of age in the cemented 
group and the corresponding proportion in the reverse hybrid 
group was 42%. Furthermore, there were significant differ-
ences regarding diagnosis, age, and sex (Table 5). In the total 
material, median follow-up was 2.9 (0–10) years in the reverse 
hybrid group and 4.7 (0–10) years in the cemented group. For 
patients aged less than 60 years, the median follow-up was 
3.4 (0–10) years for reverse hybrid and 5.2 (0–10) years for 
cemented (Table 5). 
There was no statistically significant difference in implant 
survival between cemented and reverse hybrid THRs when the 
endpoint was any revision. This was also found in analyses of 
cases less than 60 years of age (Figures 2 and 3, Table 5). In 
subanalyses of the total material using the endpoints revision 
due to deep infection, dislocation, aseptically loosened stem, 
and aseptically loosened cup, no statistically significant differ-
ences between cemented and reverse hybrid THRs were found. 
The reverse hybrids had a 3.6 times higher risk of revision 
for periprosthetic femoral fracture compared to the cemented 
implants (CI: 1.9–6.9; p < 0.001). The survival was 99.85% 
(99.8–99.9) and 99.6% (99.3–99.9), respectively, at 5 years 
using this endpoint.
We performed analyses of the different cup/stem combina-
tions in the reverse hybrid group with all revisions as the end-
point at 3 and 5 years. No statistically significant differences 
were found. Reflection PE/Hactiv and Reflection PE/Taperloc 
had less than 20 hips left at risk at 5 years; thus, 5-year sur-
vival of these combinations could not be estimated.
In the reverse hybrid group, 3,832 of the 3,963 prostheses 
had a femoral head with a diameter of 28 mm. 2,467 heads 
were made of alumina and 1,286 heads were made of cobalt 
chromium. In these 2 groups, all head sizes were included. 
Among the different groups of reverse hybrid combinations, 
we noted differences in age, in median follow–up time, and 
in the male/female ratio. The ReflectionPE/Taperloc com-
bination has been used since 2005, but maximum follow-up 
for this group only reached 4.7 years. All the other groups of 
reverse hybrid combinations had a maximum follow-up of 
more than 5 years (Table 2).
Discussion 
The use of reverse hybrids has increased in Norway and 
Sweden during the last decade. Before 2000, few reverse 
hybrid operations were performed each year, and with many 
Table 5. Comparison of demographic data for cemented and reverse hybrid THRs, both for total material and for patients aged < 60 years. Comparison of 
survival (in %) and relative risk (RR) of revision for cemented and reverse hybrid THRs, with all revisions as endpoint, for total material and for patients aged 
< 60 years 
   Total material   Age < 60 years
  Cemented   Reverse hybrid    p-value  Cemented   Reverse hybrid   p-value
n   37,666  3,963    3,480  1,647 
Revisions    1,140     108       135       41 
Median follow-up (range)   4.7 (0–10)  2.9 (0–10)   < 0.001 b  5.2 (0–10)  3.4 (0–10)   < 0.001 b
Mean age (min–max)   73 (16–98)  61 (18–92)   < 0.001 b  54 (16–60)  52 (18–60)   < 0.001 b
% < 60 years    9  42   < 0.001 a 100  100 
% male  29  36  < 0.001 a    36    39  0.06 a 
Deceased    5,928 (15.7%)     104 (2.6%)       229 (6.6%)       25 (1.5%) 
Emigrated         58 (0.2%)         8 (0.2%)         21 (0.6%)         4 (0.4%) 
Missing           2         0            0         0 
Alive  31,678 (84.1%)  3,851 (97.2%)    3,230 (92.8%)  1,618 (98.2%)
Diagnosis      < 0.001 a      < 0.001 a
 Osteoarthritis  78.6%  70.9%    56.6%  55.9%
  RA/Inflammatory    3.3%    4.2%      8.0%  6.0%
  Sequelae hip fracture    8.9%    5.2%      7.1%  4.8%
  Dysplasia    4.3%  11.6%    16.5%   20.4%
  Perthes’    0.6%    2.2%      3.1%  4.5%
  Other    4.4%    5.9%      8.7%  8.4%
3-year survival (95%CI)  97.9 (97.7–98.0)  97.7 (97.2–98.2)    98.0 (97.5–98.5)  98.3 (97.7–99.0)
5-year survival (95%CI)  97.0 (96.8–97.2)  96.7 (96.0–97.4)    96.7 (96.0–97.3)  97.5 (96.6–98.5)
7-year survival (95%CI)  96.0 (95.7–96.2)  95.6 (94.4–96.7)    94.9 (94.0–95.9)  96.2 (94.6–97.8)
RR c (95%CI)  1 (Reference)   1.1 (0.9–1.4)   0.3  1 (Reference)  0.9 (0.6–1.3)     0.5
a Chi-squared test.
b Non-parametric Mann-Whitney.
c RR adjusted for age, sex, and diagnosis.Acta Orthopaedica 2011; 82 (6): 639–645  643
different combinations of components. In this pre-2000 
period, we believe that in some instances failure to achieve 
solid fixation of an uncemented cup made the surgeon convert 
to a cemented cup. Since the year 2000, the reverse hybrid 
concept has been used more systematically in Norway and the 
number of implanted primary reverse hybrids has increased 
from 90 in the year 2000 to 1,735 in 2009. In Sweden, the 
number of hybrid THRs has declined and the total number of 
reverse hybrids has increased (Swedish Hip Arthroplasty Reg-
ister 2007). This increase in popularity called for the evalua-
tion of medium-term results using this method.
Comparing the reverse hybrid group with the 10 most used 
cemented THRs, we found similar implant survival with 0–10 
years of follow-up. The only differences found were for sub-
analyses on femoral fractures, but the difference in survival at 
5 years with this endpoint was only 0.25% and 5-year survival 
exceeded 99% for both groups. This indicates that peripros-
thetic femoral fractures are an infrequent complication lead-
ing to revision surgery.
For the total material, the proportion of males was higher 
and the mean age was lower in the reverse hybrid group than 
in the cemented group. We had no scoring for activity level, 
and there could be a bias in comparing high-demand young 
men to a group with low-demand elderly women. However, 
when we limited analyses to patients less than 60 years of 
age, the groups were much more similar to each other. The 
median follow-up for total material and for cases below 60 
years differed significantly between study groups, and with 
short follow-up it may therefore be difficult to uncover differ-
ences between these 2 concepts. 
We found similar risk of deep infection with reverse hybrid 
and cemented THR. Only revisions that included removal or 
exchange of parts or the whole implant were reported to the 
register. Thus, soft tissue revisions without the exchange of 
prosthetic parts were not reported to the NAR. For the period 
2003–2007 and using data from the NAR, Dale et al. (2009) 
found a statistically significant difference in numbers of revi-
sions due to deep infection with inferior results for uncemented 
THR compared to cemented THR. One explanation for our 
finding is that antibiotic in the cement in reverse hybrids may 
protect against deep infection (Engesaeter et al. 2003).
In the present study, 97% of the stems had HA coating and 
in the medium term we found results comparable to those for 
cemented THR (Table 4). In 2002, the NAR reported inferior 
results for 2 types of HA-coated cups as compared to cemented 
Charnley cups (Havelin et al. 2002). In 2010, Lazarinis et al. 
reported increased risk of revision of acetabular cups coated 
with HA, and in 2009 Stilling et al. reported inferior results 
for an HA-coated cup compared to those for a non HA-coated 
cup at 15 years. Concerns have been raised about third body 
wear induced by HA from HA-coated implants. Røkkum et al. 
(2002) discussed whether thick HA coatings may delaminate, 
and suggested that thick HA coatings may be a reservoir for HA 
particles. Wear and wear-related problems may appear several 
years after the primary procedure. Studies with large numbers 
and long follow-up are thus necessary in order to be able to con-
clude whether the performance of cup implants is influenced by 
the stem having an HA coating. Regarding this problem, ran-
domized controlled trials measuring wear with precise methods 
are important, but registry studies collecting a large amount of 
data on prostheses may also reveal differences between HA-
coated implants and those without any HA coating.
In the NAR, femoral fractures are reported if they require 
revision surgery. We found a higher risk of revision for peri-
prosthetic femoral fracture in the reverse hybrids than in the 
all-cemented THRs. Although it was more common with unce-
mented stems, periprosthetic femoral fracture was uncommon 
in both groups. Hailer et al. (2010) found in a study from the 
Figure 2. Cox survival curves. Endpoint was any revision of the implant 
for the total material. Adjusted for age, sex, and diagnosis. Age: < 50, 
50–59, 60–69, 70–79 and > 80. Diagnosis: OA, RA/inflammatory, or 
other. 
Figure 3. Cox survival curves. Endpoint was any revision of the implant. 
Age < 60 years. Adjustment for age, sex, and diagnosis. Age: <50, 
50–60. Diagnosis: OA, RA/inflammatory, or other.644  Acta Orthopaedica 2011; 82 (6): 639–645
Swedish Arthroplasty Register that uncemented stems were 
more frequently revised due to periprosthetic fracture than 
cemented stems during the first 2 postoperative years. 
We used the Kaplan-Meier method to estimate prosthesis 
survival, censoring death and emigration. Both death and 
emigration are competing risks regarding revision. In a study 
from the Australian Orthopaedic Association National Joint 
Replacement Registry, Gillam et al. (2010) found that the 
Kaplan-Meier method overestimated the risk of revision com-
pared to a method called the cumulative incidence function. 
The latter method uses competing risk methods in the analy-
ses. With a short- to medium-term follow-up and a rather low 
incidence of death, we assumed that the Kaplan-Meier method 
would be appropriate to use in this study.
Regarding revision due to deep infection, dislocation, 
aseptically loosened stem, and aseptically loosened cup, we 
did not find any statistically significant difference between 
cemented and reverse hybrid THRs. In planning the study, 
we aimed to do subanalyses with the endpoints revision due 
to deep infection, dislocation, aseptically loosened stem, and 
aseptically loosened cup for the different combinations of cup/
stem (different brands) in the reverse hybrid group. We found 
that the number of revisions and the number of procedures in 
some groups were quite small (Table 2). Thus, 1 single revi-
sion would have a large effect on the survival calculations 
for certain implant combinations. Although our register has a 
high completeness of data, we do not know for certain that all 
revisions of the primary THRs included were reported to the 
register. 1 or 2 missing revisions in 1 study group may offset 
the results quite dramatically when the groups are small. Fur-
thermore, the accuracy of registry results is not known; the 
surgeon may type the data into the wrong box on the form, 
or the register may enter wrong data into the database. It is 
therefore difficult to make conclusions about the performance 
of the different components used in the reverse hybrid group. 
Subtle differences between study groups, if found, should be 
interpreted with caution—even if they are statistically signif-
icant. Factors other than the implant itself, such as surgical 
technique, revision policy, incorrect registration, or unknown 
patient factors may bias the results. 
In summary, we found no statistically significant differ-
ences in survival between reverse hybrid and all-cemented 
THRs in this population-based registry study. Both groups 
performed well, with 95–96% survival after up to 7 years of 
follow-up. Thus, there were no early signs of warning against 
the reverse hybrid method according to our findings. Due to 
the small number of revisions in the present study, we cannot 
make any conclusions regarding the results for the different 
cup/stem combinations of reverse hybrid THR. With a short- 
to medium-term follow–up, it appears that the reverse hybrid 
method might be a promising alternative in THR surgery using 
UHMWPE. We emphasize that long-term follow-up will be 
required to evaluate whether the concept has any advantage 
over all-cemented THR. 
EL: conception of study, planning, interpretation of data, and writing of the 
manuscript. All the others contributed to planning, interpretation of data, and 
critical review of the manuscript. ED and AMF: statistical analysis. 
We thank all the orthopedic surgeons in Norway who contribute to the regis-
tration of joint implants, and the NAR for their continued work. 
No competing interests declared. 
Alho A, Lepisto J, Ylinen P, Paavilainen T. Cemented Lubinus and Furlog 
total hip endoprosthesis: a 12-year follow-up study of 175 hips compar-
ing the cementing technique. Arch Orthop Trauma Surg 2000; 120 (5-6): 
276-80.
Arthursson A J, Furnes O, Espehaug B, Havelin L I, Soreide J A. Validation 
of data in the Norwegian Arthroplasty Register and the Norwegian Patient 
Register: 5,134 primary total hip arthroplasties and revisions operated at a 
single hospital between 1987 and 2003. Acta Orthop 2005; 76 (6): 823-8.
Dale H, Hallan G, Hallan G, Espehaug B, Havelin L I, Engesaeter L B. 
Increasing risk of revision due to deep infection after hip arthroplasty. Acta 
Orthop 2009; 80 (6): 639-45.
Engesaeter L B, Lie S A, Espehaug B, Furnes O, Vollset S E, Havelin L I. Anti-
biotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis 
systemically and in bone cement on the revision rate of 22,170 primary hip 
replacements followed 0-14 years in the Norwegian Arthroplasty Register. 
Acta Orthop Scand 2003; 74 (6): 644-51.
Espehaug B, Furnes O, Havelin L I, Engesaeter L B, Vollset S E. The type of 
cement and failure of total hip replacements. J Bone Joint Surg (Br) 2002; 
84 (6): 832-38.
Espehaug B, Furnes O, Havelin L I, Engesaeter L B, Vollset S E, Kindseth O. 
Registration completeness in the Norwegian Arthroplasty Register. Acta 
Orthop 2006; 77 (1): 49-56.
Espehaug B, Furnes O, Engesaeter L B, Havelin L I. 18 years of results with 
cemented primary hip prostheses in the Norwegian Arthroplasty Register. 
Acta Orthop 2009; 80 (4): 402-12.
Gillam M H, Ryan P, Graves S E, Miller L N, de Steiger R N, Salter A. Com-
peting risks survival analysis applied to data from the Australian Orthopae-
dic Association National Joint Replacement Registry. Acta Orthop 2010; 
81 (5): 548-55.
Hailer N P, Garellick G, Karrholm J. Uncemented and cemented primary total 
hip arthroplasty in the Swedish Hip Arthroplasty Register. Acta Orthop 
2010; 81 (1): 34-41.
Hallan G, Lie S A, Furnes O, Engesaeter L B, Vollset S E, Havelin L I. 
Medium- and long-term performance of 11,516 uncemented primary femo-
ral stems from the Norwegian arthroplasty register. J Bone Joint Surg (Br) 
2007; 89 (12): 1574-80.
Havelin L I, Espehaug B, Vollset S E, Engesaeter L B, Langeland N. The Nor-
wegian arthroplasty register. A survey of 17,444 hip replacements 1987-
1990. Acta Orthop Scand 1993; 64 (3): 245-51.
Havelin L I, Espehaug B, Vollset S E, Engesaeter L B. The effect of the type 
of cement on early revision of Charnley total hip prostheses. A review of 
eight thousand five hundred and seventy-nine primary arthroplasties from 
the Norwegian Arthroplasty Register. J Bone Joint Surg (Am) 1995; 77 
(10): 1543-50.
Havelin L I, Engesaeter L B, Espehaug B, Furnes O, Lie S A, Vollset S E. The 
Norwegian Arthroplasty Register: 11 years and 73,000 arthroplasties. Acta 
Orthop Scand 2000a; 71 (4): 337-53.
Havelin L I, Espehaug B, Lie S A, Engesæter L B, Furnes O, Vollset S E. Pro-
spective studies of hip prostheses and cements. A presentation of the Nor-
wegian arthroplasty register 1987-1999. Scientific Exhibition presented at 
the 67th Annual Meeting of the American Academy of Orthopaedic Sur-
geons, March 15-19, 2000, Orlando, Florida, USA.www.haukeland.no/nrl/
Forskning/Publikasjoner/Academy_2000.pdf. 2000b. 15-3-2000b. Acta Orthopaedica 2011; 82 (6): 639–645  645
Havelin L I, Espehaug B, Engesaeter L B. The performance of two hydroxy-
apatite-coated acetabular cups compared with Charnley cups. From the 
Norwegian Arthroplasty Register. J Bone Joint Surg (Br) 2002; 84 (6): 
839-45.
Hulleberg G, Aamodt A, Espehaug B, Benum P. A clinical and radiographic 
13-year follow-up study of 138 Charnley hip arthroplasties in patients 
50-70 years old: comparison of university hospital data and registry data. 
Acta Orthop 2008; 79 (5): 609-17.
Lazarinis S, Karrholm J, Hailer N P. Increased risk of revision of acetabu-
lar cups coated with hydroxyapatite. A Swedish Hip Arthroplasty Register 
study involving 8,043 total hip replacements. Acta Orthop 2010; 81 (1): 
53-9.
Makela K T, Eskelinen A, Paavolainen P, Pulkkinen P, Remes V. Cementless 
total hip arthroplasty for primary osteoarthritis in patients aged 55 years 
and older. Acta Orthop 2010; 81 (1): 42-52.
McNally S A, Shepperd J A, Mann C V, Walczak J P. The results at nine to 
twelve years of the use of a hydroxyapatite-coated femoral stem. J Bone 
Joint Surg (Br) 2000; 82 (3): 378-82.
Norwegian Arthroplasty Register. Annual report 2005. Norwegian version. 
The Norwegian Arthroplasty Register 2005. 
Ranstam J, Robertsson O. Statistical analysis of arthroplasty register data. 
Acta Orthop 2010; 81 (1): 10-4.
Rokkum M, Reigstad A, Johansson C B. HA particles can be released from 
well-fixed HA-coated stems: histopathology of biopsies from 20 hips 2-8 
years after implantation. Acta Orthop Scand 2002; 73 (3): 298-306.
Stilling M, Rahbek O, Soballe K. Inferior survival of hydroxyapatite versus 
titanium-coated cups at 15 years. Clin Orthop 2009; (467) (11): 2872-9.
Swedish Hip Arthroplasty Register. Annual Report 2007: 11-5. 